Geoglim-G 1 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glycemic control. The sustained-release formulation ensures gradual drug release, promoting steady plasma concentrations and minimizing gastrointestinal side effects commonly associated with metformin. Geoglim-G 1 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It is essential to use this medication under medical supervision, with regular monitoring of blood glucose and renal function, as metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea or diarrhea, and rarely, lactic acidosis. Dose adjustments should be individualized based on therapeutic response and tolerability. This combination therapy offers a synergistic approach to managing hyperglycemia, improving patient compliance by reducing pill burden.